Big sec investigation , either they renegotiate the Medistem deal for a better price, or they get sued and sec gets involved , XON necks is on the line. State laws have been broken.
Why is it going up on this news?Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease, they will not make any money here, because there is not enough people with this disease (a rare genetic neurodegenerative disease) This is fluff PR but people with money to buy just don't understand.
News 
Market Data 
Discover 
